TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18237364
Drug: N-of-1 trials
Normalized name: (Alginate)n+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-of-1 trials (celecoxib vs paracetamol)
Study: 14676071
Drug: alefacept, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alefacept, 7.5 mg, in both courses (cohort 1)
Study: 14676071
Drug: alefacept, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alefacept, 7.5 mg, in the first course and placebo in the second course (cohort 2)
Study: 14676071
Drug: placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in the first course and alefacept, 7.5 mg, in the second course (cohort 3)
Study: 1479656
Drug: 2 sheets
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sheets of nitroglycerin patches (5 mg each)
Study: 1479656
Drug: 5 sheets
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sheets of nitroglycerin patches (5 mg each)
Study: 1479656
Drug: 10 sheets
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 sheets of nitroglycerin patches (5 mg each)
Study: 1479656
Drug: 0 sheets
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 sheets of nitroglycerin patches (control group)
Study: 6703268
Drug: Bupivacaine and
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine and Prilocaine (increased dose)
Study: 30191249
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine arm (LBA) - 20 ml 1.3% bupivacaine liposomal mixed with 10 ml 0.5% bupivacaine at the sacrospinous ligament.
Study: 30191249
Drug: Lidocaine arm
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine arm (LA) - 30 ml 0.5% lidocaine with 1:200,000 epinephrine local injection at the sacrospinous ligament.
Study: 21586127
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment
Study: 17353373
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPD) 0.4 mg/kg administered orally 3 times per day
Study: 14732641
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and written communication about the risks of the procedure (pamphlet)
Study: 14732641
Drug: Oral communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral communication about the risks of the procedure (no pamphlet)
Study: 14732641
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and written communication (pamphlet)
Study: 31381494
Drug: Water-soluble chicken
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble chicken eggshell membrane (WSEM) 450 mg daily
Study: 23035749
Drug: six 4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: six 4‐mg doses of betamethasone every 8 h
Study: 23035749
Drug: two 12‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 12‐mg doses of betamethasone separated by 24 h
Study: 12002834
Drug: occlusal splints
Approvals — FDA: no, EMA: no, PMDA: no
Description: occlusal splints and supplementary medical therapy (group II)
Study: 12002834
Drug: occlusal splints
Approvals — FDA: no, EMA: no, PMDA: no
Description: occlusal splints and physical therapy (group III)
Study: 12002834
Drug: occlusal splints,
Approvals — FDA: no, EMA: no, PMDA: no
Description: occlusal splints, medical, and physical therapy (group IV)
Study: 2223143
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan (0.25 mg/kg/day) with oral prednisone (2 mg/kg/day)
Study: 2223143
Drug: Intravenous melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous melphalan (0.125 mg/kg/day) with oral prednisone (2 mg/kg/day)
Study: 333855
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg - 40 mg)
Study: 28538781
Drug: Passive cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive cycling exercise combined with conventional physical therapy (5 days per week)
Study: 28538781
Drug: Passive cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive cycling exercise combined with conventional physical therapy
Study: 20925442
Drug: Vardenafil ODT
Normalized name: Vardenafil Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil ODT (10 mg)
Study: 20925442
Drug: Vardenafil FCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil FCT (film-coated tablet)
Study: 11554127
Drug: Azathioprine 100
Normalized name: azathioprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 100 mg/day for 6 weeks
Study: 9630326
Drug: CsA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA at a dosage of 1 mg/kg/die (CsA1)
Study: 9630326
Drug: CsA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA at a dosage of 3 mg/kg/die (CsA3)
Study: 3050268
Drug: High NaCl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NaCl diet (20 g/day)
Study: 3050268
Drug: Low NaCl
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NaCl diet (2 g/day)
Study: 29354989
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Pinaverium bromide tablet, 50 mg, 3 times a day)
Study: 25230980
Drug: Polypill (hydrochlorothiazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (hydrochlorothiazide, aspirin, atorvastatin, and either enalapril or valsartan)
Study: 18811828
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch solution 130/0.42 (HES)
Study: 18811828
Drug: 4% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% modified fluid gelatin (GEL)
Study: 16543549
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy arm of the National Emphysema Treatment Trial
Study: 9384477
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days), and cyclophosphamide (35 mg/kg x 4 days) followed by infusion of unmanipulated PBSC.
Study: 9384477
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients who had failed primary induction chemotherapy (28 patients).
Study: 9384477
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients in untreated first relapse (27 patients).
Study: 9384477
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients who had reinduction attempts prior to receiving mobilization chemotherapy (18 patients).
Study: 1585757
Drug: Micanol (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micanol (new dithranol formulation)
Study: 30575682
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (>12 g/day) with NTG
Study: 30575682
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (>12 g/day) without NTG
Study: 30575682
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (<3 g/day) with NTG
Study: 30575682
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (<3 g/day) without NTG
Study: 30575682
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (>12 g/day) with large body weight change
Study: 30575682
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (>12 g/day) with small body weight change
Study: 24825768
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in Group 1 (37 patients)
Study: 24825768
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in Group 2 (18 patients)
Study: 20664537
Drug: Oltipraz (30-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz (30-90 mg single dose; 60 mg b.i.d. or 90 mg q.d. for 24 weeks)
Study: 15639067
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 800 mug
Study: 15639067
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 800 mug
Study: 8435265
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg kg-1
Study: 8435265
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg kg-1
Study: 2448425
Drug: 10% hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydroxyethylstarch (HES), 500 ml daily for 7 days
Study: 2448425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without HES infusion
Study: 29924703
Drug: Protein-enhanced diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enhanced diet (1.2 g protein/kg body weight/day with 30 g protein/meal), n=41
Study: 29924703
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.8 g protein/kg body weight/day), n=21
Study: 26850888
Drug: Optimized group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized group 1 (individualized treatment in 30 DM cases)
Study: 29335895
Drug: Rilpivirine 25
Normalized name: rilpivirine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine 25 mg once daily
Study: 16564942
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (300 mg with each dialysis session)
Study: 16492717
Drug: Fontolizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab 0.1 mg/kg
Study: 16492717
Drug: Fontolizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab 1.0 mg/kg
Study: 16492717
Drug: Fontolizumab 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab 4.0 mg/kg
Study: 16492717
Drug: Fontolizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fontolizumab (all doses)
Study: 10840987
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (500 ml/day)
Study: 23879615
Drug: Immediate functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate functional loading implants (test group 1) with conventional drilling procedure
Study: 23879615
Drug: Immediate functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate functional loading implants (test group 2) with modified implant installation procedure (osteotome technique)
Study: 23879615
Drug: Conventional drilling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drilling procedure with submerged implants for 3 months (control group)
Study: 23879615
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants (combined data)
Study: 21951832
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg qd
Study: 18165450
Drug: Long chain
Normalized name: long chain triglycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long chain triglycerides (LCT) infusion for 5 days postoperatively
Study: 18165450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LCT infusion)
Study: 17198491
Drug: Experimental nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental nutritional formula (EXP) 240 mL/d for 4 weeks before and 6 weeks after influenza vaccination
Study: 10928427
Drug: i.m. progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. progesterone formulation, 50 mg
Study: 8628712
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 7 gms/L of fiber
Study: 8628712
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 14 gms/L of fiber
Study: 3893732
Drug: MDL 72,222
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72,222 (20-40 mg)
Study: 29885997
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT, followed by 3 cycles of cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/day for 4 days)
Study: 29885997
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT
Study: 27668585
Drug: CT-guided lumbosacral
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided lumbosacral facet joint injection of methylprednisolone acetate (0.1 mg/kg)
Study: 27668585
Drug: CT-guided transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided transforaminal epidural injection of methylprednisolone acetate (0.1 mg/kg)
Study: 27668585
Drug: CT-guided translaminar
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided translaminar epidural injection of methylprednisolone acetate (0.1 mg/kg)
Study: 24019126
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg orally, twice daily, 4 and 3 hours before each radiotherapy fraction
Study: 20305869
Drug: 25% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% citric acid solution
Study: 20305869
Drug: 24% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% EDTA gel
Study: 20305869
Drug: tetracycline solution
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline solution (50 mg/mL)
Study: 20305869
Drug: 30% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% sodium citrate solution
Study: 20305869
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution irrigation
Study: 15549690
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum (St. John's Wort), duration of treatment not specified.
Study: 15549690
Drug: Not applicable,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable, as the study mentions that beliefs did not mediate the effect of treatment on depression.
Study: 8516819
Drug: Monoclonal IL‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal IL‐2 receptor antibody therapy as part of a quadruple immunosuppressive regimen
Study: 8516819
Drug: ATG as
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG as induction therapy
Study: 31096036
Drug: Umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg
Study: 24830577
Drug: OSS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSS plus SF‐ELS (split dose)
Study: 24830577
Drug: OSS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSS plus SF‐ELS (entire dose)
Study: 24830577
Drug: PEG‐EA (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐EA (split dose)
Study: 24830577
Drug: Bisacodyl plus
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisacodyl plus SF‐ELS (same-day preparation)
Study: 19407953
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine combined with acitretin capsule
Study: 19407953
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine alone
Study: 19407953
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Chinese herbal medicine with and without acitretin)
Study: 17574073
Drug: Histologic type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histologic type (S, CC, E)
Study: 17574073
Drug: Histology (S,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histology (S, CC)
Study: 16264181
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of adjuvant tamoxifen therapy
Study: 16264181
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of adjuvant tamoxifen therapy
Study: 10901847
Drug: Antiretroviral (ARV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral (ARV) drugs (zidovudine with or without lamivudine or nevirapine)
Study: 10901847
Drug: Confidential, voluntary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidential, voluntary HIV screening and counseling of pregnant women with short-course ARV treatment during the perinatal period
Study: 10901847
Drug: Post-exposure prophylaxis
Normalized name: Anthrax, post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-exposure prophylaxis using ARV drugs in newborns
Study: 8848900
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) administered continuously during 60 min
Study: 1691806
Drug: Aprotinin infusion
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin infusion (total 6.10(6) KIU) before and during bypass
Study: 451497
Drug: 10% glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycerol solution
Study: 451497
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution (placebo)
Study: 31083231
Drug: 3.7 MBq
Normalized name: Sodium iodide (123-I) 3.7 MBq oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.7 MBq I‐131/g thyroid plus 600 mg/day LiCO3
Study: 31083231
Drug: 5.55 MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.55 MBq I‐131/g plus 600 mg/day LiCO3
Study: 31083231
Drug: 7.4 MBq
Normalized name: Sodium iodide (123-I) 7.4 MBq oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4 MBq I‐131/g without LiCO3
Study: 31083231
Drug: 7.4 MBq
Normalized name: Sodium iodide (123-I) 7.4 MBq oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4 MBq I‐131/g
Study: 25582309
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of iron (Fe) plus 30 mg of zinc (Zn) for 3 months
Study: 25582309
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of zinc (Zn) plus 30 mg of iron (Fe) for 3 months
Study: 23580239
Drug: sorafenib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 600 mg twice daily
Study: 19211442
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin
Study: 16895892
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1140 mg/d
Study: 16895892
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake range (700-2100 mg/d)
Study: 15098883
Drug: Leuprorelin, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin, 0.5 mg/d subcutaneously (group A)
Study: 15098883
Drug: Leuprorelin, 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin, 3.75 mg depot (group B)
Study: 8036680
Drug: Primaquine 15
Normalized name: primaquine 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 15 mg for 14 days
Study: 8036680
Drug: Primaquine 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 22.5 mg for 14 days
Study: 8036680
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg on the first day
Study: 8036680
Drug: Chloroquine 450
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 450 mg on the first day
Study: 2675651
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg tablets taken four times a day for 4 to 6 days
Study: 1266277
Drug: Imipramine 25
Normalized name: trimipramine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 25 mg (22.1 mg free base)
Study: 1266277
Drug: Dimetacrine 33.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimetacrine 33.5 mg (21.4 mg free base)
Study: 1266277
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants during ergometric exercise
Study: 31945895
Drug: STAR-IO (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-IO (insulin only version)
Study: 28189364
Drug: SC401 (1530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC401 (1530 mg EPA‐ethyl esters and DHA‐EEs)
Study: 28189364
Drug: Lovaza (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (3600 mg ω‐3)
Study: 22277329
Drug: HPV16/18 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16/18 antibody or DNA testing